Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Yu Yan, Kanwaldeep Singh, Emily Hartung, Brendan Lee, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Brian Leber, Irwin Walker, Kylie L. Lepic, Maria Kleppe, Hugh Young Young Rienhoff Jr., Jr., Jonathan Bramson, Tobias Berg

Blood (2023) 142 (Supplement 1): 6793.

https://doi.org/10.1182/blood-2023-188472

Published: 2023

Journal Articles

Concurrent BCR::-ABL1 and CBFB Rearrangement in De Novo Acute Myeloid Leukemia

Brittany Salter, Shiliang Ge, Dina Khalaf, Elizabeth McCready, Amy Tam, Darci Butcher, Suzanne Demczuk

Blood (2023) 142 (Supplement 1): 5866.

https://doi.org/10.1182/blood-2023-186092

Published: 2023

Journal Articles

Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant

Michael Radford, Alejandro Garcia-Horton, Rohail Badami, Elaine Jin, Nida Javed Usmani, Daria Grafodatskaya, Elizabeth McCready, Dina Khalaf, Irwin Walker, Brian Leber, Kylie L. Lepic, Gregory Pond, Tobias Berg

Blood (2023) 142 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2023-187458

Published: 2023

Journal Articles

Ureaplasma -Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant

Rohail Badami, Kylie L. Lepic, Dina Khalaf, Alejandro Garcia-Horton, Tobias Berg, Brian Leber, Irwin Walker, Michael Radford

Blood (2023) 142 (Supplement 1): 6988.

https://doi.org/10.1182/blood-2023-182897

Published: 2023

Journal Articles

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Kanwaldeep Singh, Emily Hartung, Christina Muhs, Islam Alshamleh, Monisha Divakaran, Anna Dvorkin-Gheva, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Stephen Ronan Foley, Brian Leber, Irwin Walker, Kylie Lepic, Harald Schwalbe, Hubert Serve, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2023) 142 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2023-189515

Published: 2023

Journal Articles

A Retrospective Cohort Study of Donor Cell Leukemia

Brittany Salter, Omar Raslan, Suzanne Demczuk, Brian Leber, Alejandro Garcia-Horton, Irwin Walker, Tobias Berg, Darci Butcher, Kylie L. Lepic, Elizabeth McCready, Parveen Wasi, Dina Khalaf

Blood (2022) 140 (Supplement 1): 12916–12917.

https://doi.org/10.1182/blood-2022-164643

Published: 2022

Journal Articles

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Blood (2022) 140 (Supplement 1): 9122–9124.

https://doi.org/10.1182/blood-2022-171107

Published: 2022

Journal Articles

Fitness Assessment of Elderly Patients with AML and Outcomes

Tony HT Chen, Joshua Xu, Hassan Zahreddine, Brian Leber, Irwin Walker, Tobias Berg, Kylie L. Lepic, Parveen Wasi, Tom Kouroukis, Christopher M. Hillis, Justin Y. Lee, Dina Khalaf

Blood (2021) 138 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2021-152612

Published: 2021

Journal Articles

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

Eugene Brailovski, Qing Li, Ning Liu, Brian Leber, Dina Khalaf, Mitchell Sabloff, Grace Christou, Karen Yee, Lisa Chodirker, Anne Parmentier, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Ying Liu, Craig C. Earle, Matthew Cheung, Nicole Mittman, Rena J. Buckstein, Lee Mozessohn

Blood (2021) 138 (Supplement 1): 3064.

https://doi.org/10.1182/blood-2021-149855

Published: 2021

Journal Articles

High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140065

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138943

Published: 2020

Journal Articles

Chronic Lymphocytic Leukemia Treatment in México: Up to Half Patients May Not Requiere Treatment

Luisa Fernanda Sánchez-Valledor, MD, Carmina Alejandra Córdova-Ramírez, Gilberto David Elias-de-la-Cruz, MD, Montserrat Rivera-Álvarez, MD, Antonio Cruz-Mora, MD, Yahveth Cantero-Fortiz, MD, Dina Khalaf, BSc, MSc, MD, Juan Carlos Olivares-Gazca, MD, Andrés A. León-Peña, MD, Iván Murrieta-Álvarez, MD, Guillermo J. Ruiz-Delgado, MD FACP, Guillermo J. Ruiz-Argüelles, FRCP, MACP, DSc(hon)

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134066

Published: 2020

Journal Articles

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Tracy Murphy, MDFRCP,FRCPath, Brian Leber, MD, Mark R Bray, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Aaron D Schimmer, MD PhD, Andre C. Schuh, Hassan Sibai, MBBS, Graham Fletcher, Debbie Valiquette, Kylie Martin, BSc, RN, BSN, Mark D. Minden, Karen W.L. Yee, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-138822

Published: 2020

Journal Articles

Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-141635

Published: 2020

Journal Articles

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

Blood (2017) 130 (Supplement 1): 2596.

https://doi.org/10.1182/blood.V130.Suppl_1.2596.2596

Published: 2017

Journal Articles

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Dina Khalaf, MD BSc, Steven M. Chan, MD PhD, Vikas Gupta, MD PhD, Andrzej Lutynski, MD, Dawn Maze, MD FRCPC, MSc, Mark D. Minden, MD PhD, Yoichiro Natori, MD, Rhea Pavan, BA, Amr Rostom, MD, Anna Rydlewski, MD, Aaron Schimmer, MD PhD, Andre Schuh, MD FRCPC, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Shahid Husain, MD MS

Blood (2017) 130 (Supplement 1): 4682.

https://doi.org/10.1182/blood.V130.Suppl_1.4682.4682

Published: 2017

Journal Articles

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Sara Farshchi Zarabi, MD, Steven M. Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Mark D. Minden, MD PhD, Amr Rostom, MD, Anna Rydlewski, MD, Andre C. Schuh, MD FRCPC, Hassan Sibai, MD, Karen W.L. Yee, MD, Aaron D. Schimmer, MD PhD

Blood (2016) 128 (22): 2800.

https://doi.org/10.1182/blood.V128.22.2800.2800

Published: 2016

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

Journal Articles

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Joseph Brandwein, MD FRCPC, Vikas Gupta, MD FRCP, FRCPath, Johann Hitzler, MD FRCP (C), FAAP, Dina Khalaf, BSc, MSc, MD, Andrzej Lutynski, MD, Aaron D. Schimmer, MD PhD, Andre C Schuh, MD FRCPC, Amr Rostom, MD, Anna Rydlewski, MD, Karen W.L. Yee, MD, Mark D. Minden, MD PhD

Blood (2015) 126 (23): 3717.

https://doi.org/10.1182/blood.V126.23.3717.3717

Published: 2015

NARROW

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Concurrent BCR::-ABL1 and CBFB Rearrangement in De Novo Acute Myeloid Leukemia

Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant

Ureaplasma -Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

A Retrospective Cohort Study of Donor Cell Leukemia

The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Fitness Assessment of Elderly Patients with AML and Outcomes

The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes

High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Chronic Lymphocytic Leukemia Treatment in México: Up to Half Patients May Not Requiere Treatment

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study

Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only